Optimistic Buy Rating for Gilead Sciences: Anticipated EPS Growth and Strong Performance in 2024
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
RBC Capital Remains a Hold on Gilead Sciences (GILD)
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with ...
Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
DelveInsight's 'Tuberculosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline tuberculosis ...
BioSpace3d
Almost 5 Years into $5B Galapagos Partnership, Gilead Execs Start Over With New Spinoff
Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...
Zacks.com on MSN4d
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
The latest trading session saw Gilead Sciences (GILD) ending at $92.96, denoting a +1.22% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of ...